These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12690374)

  • 41. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
    Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
    J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topical beta-blockers in patients with co-existing conditions: is this a cause for concern?
    Good CB
    Pharmacoepidemiol Drug Saf; 2001; 10(6):509-10. PubMed ID: 11828832
    [No Abstract]   [Full Text] [Related]  

  • 43. [Use of glaucoma medications during pregnancy and breastfeeding].
    Méndez-Hernández C
    Arch Soc Esp Oftalmol; 2012 Dec; 87(12):389-91. PubMed ID: 23121698
    [No Abstract]   [Full Text] [Related]  

  • 44. Prophylactic brimonidine before LASIK.
    Uretmen O; Ates H; Andaç K
    J Refract Surg; 2003; 19(5):612. PubMed ID: 14518756
    [No Abstract]   [Full Text] [Related]  

  • 45. Effect of brimonidine 0.5% on intraocular pressure spikes following 360% argon laser trabeculoplasty. The Brimonidine-ALT Study Group.
    Ophthalmic Surg Lasers; 1995; 26(5):404-9. PubMed ID: 8963853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate.
    Vanhaesebrouck S; Cossey V; Cosaert K; Allegaert K; Naulaers G
    Eur J Ophthalmol; 2009; 19(4):694-5. PubMed ID: 19551691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brimonidine tartrate for the treatment of glaucoma.
    Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
    Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
    Lee DA; Gornbein J; Abrams C
    J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
    Aristodemou P; Baer R
    Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of alpha-agonists in glaucoma therapy.
    Robin AL
    Curr Opin Ophthalmol; 1997 Apr; 8(2):42-9. PubMed ID: 10168356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs.
    Tanna AP; Rademaker AW; Stewart WC; Feldman RM
    Arch Ophthalmol; 2010 Jul; 128(7):825-33. PubMed ID: 20625041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does topical brimonidine tartrate help NAION?
    Fazzone HE; Kupersmith MJ; Leibmann J
    Br J Ophthalmol; 2003 Sep; 87(9):1193-4. PubMed ID: 12928304
    [No Abstract]   [Full Text] [Related]  

  • 56. Resting pulse rates in a glaucoma clinic: the effect of topical and systemic beta-blocker usage.
    Tattersall C; Vernon S; Singh R
    Eye (Lond); 2006 Feb; 20(2):221-5. PubMed ID: 15803169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
    Becker HI; Walton RC; Diamant JI; Zegans ME
    Arch Ophthalmol; 2004 Jul; 122(7):1063-6. PubMed ID: 15249377
    [No Abstract]   [Full Text] [Related]  

  • 58. Antiglaucoma medications: a review of safety and tolerability issues related to their use.
    Schuman JS
    Clin Ther; 2000 Feb; 22(2):167-208. PubMed ID: 10743979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Anterior uveitis and topical brimonidine: a case report].
    Velasque L; Ducousso F; Pernod L; Vignal R; Deral V
    J Fr Ophtalmol; 2004 Dec; 27(10):1150-2. PubMed ID: 15687926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
    Kaneko E; Wada T; Minagawa Y; Inoue Y
    Nihon Yakurigaku Zasshi; 2012 Oct; 140(4):177-82. PubMed ID: 23059902
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.